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Available online 23 March 2016Herewe describe some of the crucial steps to generate induced pluripotent stem cells (iPSCs) usingmRNA trans-
fection. Our approach uses a V. virus-derived capping enzyme instead of a cap-analog, ensuring 100% proper cap
orientation for in vitro transcribedmRNA. V. virus' 2′-O-Methyltransferase enzyme creates a cap1 structure found
in higher eukaryotes and has higher translation efﬁciency compared to other methods. Use of the polymeric
transfection reagent polyethylenimine proved superior to other transfection methods.
The mRNA created via this method did not trigger an intracellular immune response via human IFN-gamma
(hIFN-γ) or alpha (hIFN-α) release, thus circumventing the use of suppressors. Resulting mRNA and protein
were expressed at high levels for over 48h, thus obviating daily transfections. Using thismethod,we demonstrat-
ed swift activation of pluripotency associated genes in human ﬁbroblasts. Low oxygen conditions further facili-
tated colony formation. Differentiation into different germ layers was conﬁrmed via teratoma assay.
Reprogramming with non-synthetic mRNA holds great promise for safe generation of iPSCs of human origin.
Using the protocols described herein we hope to make this method more accessible to other groups as a fast,
inexpensive, and non-viral reprogramming approach.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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mRNA1. Introduction
The initial approach for deriving iPSCs used retroviral vectors to de-
liver reprogramming factors into cells (Takahashi & Yamanaka, 2006;
Takahashi et al., 2007). Although this method is straightforward,
reliable, and easily adoptable by labs, its therapeutic application is
precluded because of the risks associated with genomic integration of
viral sequences.
Different non-integratingmethods for generating human iPSCs have
been reported (Stadtfeld et al., 2008; Yu et al., 2009; Jia et al., 2010; Yusa
et al., 2009; Warren et al., 2010; Hou et al., 2013). The strengths and
weaknesses of these methodologies are under consideration
(Robinton & Daley, 2012; Zhou & Zeng, 2013).
Several groups have used mRNA for reprogramming with various
degrees of success (Plews et al., 2010; Warren et al., 2012; Yakubov
et al., 2010; Tavernier et al., 2012; Mandal & Rossi, 2013; Heng et al.,
2013). This method is not well established. An obstacle has been the ac-
tivation of an innate immune response following mRNA transfectionnited Kingdom.
. This is an open access article underresulting in severe cytotoxicity (Angel & Yanik, 2010; Drews et al.,
2012). The mechanism may depend on the nature of the mRNA used
for reprogramming (Karikó et al., 2005; Karikó & Weissman, 2007;
Karikó et al., 2008). Previous studies incorporated modiﬁed nucleosides
into mRNA (substitution of cytidine and uridine with pseudouridine
and 5-methylcytidine) to abrogate the innate immune response. How-
ever residual upregulation of some interferon gene targets has still
been detected (Warren et al., 2010; Warren et al., 2012; Mandal &
Rossi, 2013).
We recently reported that iPSCs can be generated using non-
modiﬁed mRNA (Arnold et al., 2012). In this report we will focus on
the crucial steps for successfully applying this method.
2. Material and methods
2.1. Cell culture
Human foreskin ﬁbroblast (HFF) was obtained with informed con-
sent (approved by University of Leipzig; Reference No.: 054-09/
09,032,009). Human IMR90 fetal ﬁbroblasts were from ATCC Global
Bioresource Centre. Fibroblast culturemediumwas DMEMhigh glucosethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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broblasts (MEFs) were established from dissociated CD1mouse embry-
os (13.5–14 d gestation) and inactivated by gamma irradiation (25 Gy).
iPSCs were expanded mechanically and cultured at 5% O2. iPS medi-
um contained Knockout™ DMEM (Life Technologies) supplemented
with 20% Knockout™ serum replacement (KSR) (Life Technologies),
10 ng/ml FGF-basic (Peprotech), 1% nonessential amino acids (Life
Technologies), 2 mM L-Glutamine (Life Technologies), 1% penicillin–
streptomycin (Life Technologies) and 0.1 mM 2-mercaptoethanol
(Sigma-Aldrich). Differentiated parts of the colonies were removed
and undifferentiated parts were cut into small pieces. Pieces were lifted
up with a ﬁlter tip and transferred onto a new plate with pre-coated ir-
radiated MEFs (iMEFs). Passaging was done in the presence of 10 μM
rho-associated kinase (ROCK) inhibitor Y-27632 (Calbiochem). Medi-
um was changed at day 2 after cell seeding and then every day until
the cells were ready for the next passage. The viral-iPSCs were passaged
every 4 days, while the mRNA-iPSCs were expanded once a week.
2.2. Generation of DNA templates
Plasmids based upon the pcDNA3™ (Life Technologies) backbone
containing either hNanog, hOct4, hKlf4, hSox2, hc-Myc, hTERT or
tagGFP. Cloning strategy and plasmid construction is shown exemplary
for hTERT in Supplementary Fig. 1. For in vitro transcription (IVT) up to
2000 nucleotides (nt) either linearized plasmid or PCR product was
used as a template. For IVT ofmRNA longer than 2000 nt only PCR prod-
ucts were used. All PCR products contained the T7-promoter followed
by the gene coding region. Plasmids were linearized at the end of the
gene coding region using the appropriate restriction endonuclease
(Thermo Fisher or New England Biolabs). Linearized plasmids and PCR
products were puriﬁed with GeneJet PCR puriﬁcation kit (Thermo
Fisher).
2.3. PCR protocol for IVT templates up to 2000 bp
PCR reactions (25 μl) contained: 1-5 ng plasmid, 2 units Platinum
Taq polymerase (Life Technologies), 1× PCR buffer w/o MgCl2, 2.8 mM
MgCl2, 0.5 μM of each sense and antisense primer (primer sequences
are included in the Supplementary Table 1) and 200 μm of each
dNTP (Thermo Fisher). PCR was performed using the TProfessional
(Biometra)with the following cycling conditions: 95 °C for 3min, 35 cy-
cles at 95 °C for 30 s, 60 °C for 30 s, 72 °C for 60 s per 1 kb and a ﬁnal
elongation step 72 °C for 3 min.
2.4. PCR protocol for IVT templates over 2000 bp
PCR reactions (50 μl) contained: 10 ngplasmid, 5 units LongAmpTaq
DNA (New England Biolabs), 1× LongAmp Taq Reaction Buffer, 300 μm
of each dNTP (Thermo Fisher), 2 μMof each sense and antisense primer
(primer sequences are included in the Supplementary Table 1). PCRwas
performed using the TProfessional (Biometra) with the following cy-
cling conditions: 95 °C for 3 min, 35 cycles at 94 °C for 10 s, 60 °C for
s, 65 °C for 50 s per 1 kb and a ﬁnal elongation step 65 °C for 3 min.
2.5. mRNA IVT
1 μg linearized plasmid or 0.5 μg PCR product was used as tem-
plate for IVT using the T7mScript Standard mRNA Production System
(Epicentre Biotechnologies). The reaction time for the T7-RNA-
polymerase transcription step was 3 h for all templates. For hTERT
different temperatures were used: 32 °C, 37 °C and 42 °C. Subsequently
a cap1 structurewas enzymatically added to the IVT-RNA using V. virus-
derived capping enzyme and 2′-O-methyltransferase, followed by
addition of a Poly(A)tail using mScript™ poly(A) polymerase enzyme
according to the manufacture's recommendations (Epicentre Biotech-
nologies). RNA puriﬁcation was performed using the GeneJet RNApuriﬁcation kit (Thermo Fisher) and a concentration was measured
using a NanoDrop1000 photometer (Peqlab). The quality and size of
the IVT mRNA was assessed by electrophoresis in a 1% agarose gel
stained with ethidium bromide or by capillary electrophoresis with
the Agilent 2100 Bioanalyzer (Agilent Technology). For the agarose
electrophoresis the RNA samples were loaded with 2× RNA loading
dye (Thermo Fisher) directly or after a heat denaturation for 10 min
at 70 °C followed by incubation on ice for 3 min. For the capillary elec-
trophoresis the Agilent RNA 6000 Nano kit was used according to the
manufacture's protocol.
2.6. mRNA transfection
Transfections were carried out with nucleofection (NHDF–VPD-
1001, Lonza), FuGENE HD (Roche), jetPEI (Polyplus) and Lipofectamine
2000 (Life Technologies). Transfections with Nucleofectin and FuGENE
HD were carried out as described previously (Arnold et al., 2012).
For jetPEI transfections, the cells (HFF at passages 7–10, and IMR90
ﬁbroblasts at passage 6) were seeded on 6-well-plates (200,000 cells/
well) 1 day prior to the experiment. Culture media was changed to
OPTI-MEM basal media (Life Technologies) before transfection. Either
3 μg of mRNA for Oct4 (O), Sox2 (S), Klf4 (K), c-Myc (M), Nanog (N),
hTERT (T) and GFP or 3 μg mixture of the reprogramming factors-
mRNA (equal amounts of each factor) was diluted in 150 mM sodium
chloride solution (PolyPlus). JetPEI was dispersed in 150 mM sodium
chloride solution. These components were incubated 30 min at RT be-
fore being dispensed to culturemedia. 4 h after transfection themedium
was changed to either ﬁbroblast or iPS medium.
For Lipofectamine 2000 transfections, HFFs were seeded on 6-well-
plates (200,000 cells/well) at passage 3 1 day prior to experiments.
3 μg of mRNA and Lipofectamine 2000 were diluted in OPTI-MEM
basalmedia and thendelivered to culturemedia after 20min incubation
at RT. 4 h after transfection the medium was changed to ﬁbroblast
medium.
2.7. Toxicity assay
Cells were seeded on 48-well plates at a density of 20,000 cells per
well. One day after seeding, the cells were incubated with mRNA-
jetPEI and mRNA-lipofectamine 2000. Viability was detected using the
MTT assay, 24 h, 48 h and 72 h after transfection. Brieﬂy, the medium
of the cells was replaced with 250 μl of fresh ﬁbroblast medium and
25 μl of MTT solution (Thiazylblau in 1× PBS−, Applichem) for each
well, followed by 4 h incubation at 37 °C. MTT solution was aspirated
after 4 h and reaction stopped by an addition of 250 μl of stop solution
containing 50% dimethyl sulfoxide (VWR International) and 50% SDS
solution (Merk Millipore). Plates were incubated at 37 °C for 1 h and
the absorbancewasmeasured using a microplate reader (Tecan Inﬁnity
Pro 200 series) at 550 nm and 630 nm as a reference wavelength.
2.8. Measurement of interferons by ELISA
Level of hIFN-γ and -α was detected in the supernatant of mRNA-
transfected cells after the ﬁrst transfection by ELISA (Mini ELISA Devel-
opment Kit, Peprotech) according to the manufacturer's instructions.
2.9. Flow cytometry
mRNA-transfected cells were trypsinized 24 h, 48 h and 72 h after
transfection, washed with PBS− and ﬁxed in 4% paraformaldehyde
(Thermo Scientiﬁc) for 15 min. Fixed cells were washed with PBS−/1%
BSA, then permeabilized with 0.2% Tween 20 (Sigma) in PBS− at 37 °C
for 10 min. Cells were blocked with PBS− containing 10% BSA (Sigma)
at 37 °C for 30min, then incubated for 1 h at 4 °Cwith the following pri-
mary antibodies: Oct4 (1:600, Cell Signaling), Sox2 (1:300, Cell Signal-
ing), c-Myc (1:200, Cell Signaling), Nanog (1:400, Cell Signaling), Klf4
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were incubated with secondary antibodies Alexa ﬂuor 488 (1:2000,
Invitrogen) and Alexa ﬂuor 546 (1:2000, Invitrogen) for 1 h at 4 °C,
suspended in PBS− and analyzed by ﬂow cytometry (BD FACS Calibur).
Non-transfected cells and cells stained with secondary antibody were
used as controls. All other data were compared to the controls. Ten
thousand gated events were collected per sample.
2.10. Reprogramming
Human foreskin or IMR90 ﬁbroblasts were seeded on 6-well-plates
pre-coated with 0.1% gelatin (Sigma-Aldrich). Cells were transferred
to 5% O2 1 day prior to the experiment. Repeated mRNA transfections
were performed using a jetPEI transfection. Different factor combina-
tions, ONT, OSK and OSKMNT were tested. 4 h after transfection the
medium was changed to iPS medium equilibrated at 5% O2 for approx-
imately 2 h before use. Transfections were performed every 48 h for
2 weeks. mRNA-iPS colonies were manually picked and transferred on
iMEFs.
2.11. Immunostaining
mRNA-transfected cells were ﬁxed with 4% paraformaldehyde 24 h
after transfection, washed and permeabilized with 0.5% Triton X-100
in PBS− (Life Technologies) for 30 min and blocked with 10% FCS in
PBS− for 1 h. Cells were incubated with primary antibodies in PBS−,
1% FCS, and 0.5% Triton X-100 at 4 °C for 1 h. After washing 3 times,
cells were incubated with secondary antibody in PBS− for 30 min at
4 °C. The primary antibodies were Oct4 (1:400), Sox2 (1:400), c-Myc
(1:800), and Nanog (1:400) (all from Cell Signaling Technology). Sec-
ondary antibody was Alexa ﬂour 488 (1:1000, Invitrogen). Nuclei
were counterstained with 4, 6-diamidino-2-phenylindole dilactate
(DAPI; 1:10,000, Sigma). HFF-mRNA-iPS colonies and HFFs were ﬁxed
and stained using the above procedure. All cells were visualized using
a ﬂuorescence microscope (Axio Observer, Zeiss).
2.12. Teratoma formation
The teratoma formation assay was performed as previously de-
scribed (Dressel et al., 2009; Dressel et al., 2010). The experiments
have been approved by the Niedersächsisches Landesamt für
Verbraucherschutz und Lebensmittelsicherheit. Immunodeﬁcient
RAG2−/−γc−/− mice were injected subcutaneously with 1 × 106
IMR90-mRNA-iPSCs in 50 μl PBS−mixedwith 50 μl Matrigel (BD Biosci-
ences). Tumor growthwasmonitoredweekly by palpation and sizewas
recorded using linear calipers. Animals were sacriﬁced when a tumor
diameter of 1 cm was reached or after 3 months. Autopsies were per-
formed and tumor tissuewas placed in phosphate-buffered 4% formalin
for 16 h and then embedded in parafﬁn. For histological examination,
tissue sections (2 μm) were stained with hematoxylin and eosin.
2.13. Karyotyping
IMR90-mRNA-iPSCs and IMR90 ﬁbroblasts were incubated with
0.1 ml Colcemid (100 mg/l isotonic NaCl solution) (Life Technologies)
for 3 h at 37 °C. Cells were collected by cell scraper and placed in a hy-
potonic solution (0.075 M KCl solution) (B. Braun Medical Inc.) at RT.
Cells were centrifugation and ﬁxed with methanol (VWR) and acetic
acid (VWR) (3:1) for 5 min followed by spreading the cells on micro-
scopic glass slides and let air dry. Trypsin-Giemsa (Dr. K. Hollborn &
Söhne GmbH & Co. in Leipzig) staining (GTG-banding) of the chromo-
somes was performed by treating the glass slides with trypsin solution
(0.5 g trypsin in 250 ml isotonic NaCl solution) for 10-20s, washed
twice with 0.9% NaCl and stained using Giemsa solution (5 ml Giemsa
stock solution in 150ml Soerensen buffer) for 5 min. The total analyzed
metaphases for IMR90 ﬁbroblasts were 25 and for IMR90-mRNA-iPSCswere 20. Analysis of karyotyped cells was performed using GeneASI
BandView software (Applied Spectral Imaging).
2.14. Quantitative RT–PCR
Total RNA was extracted using Trifast reagent according to the
manufacturer's instructions (Peqlab) and treated with DNaseI (Thermo
Scientiﬁc). cDNA was synthesized using Superscript III (Life Technolo-
gies) and Oligo(dT)18-Primers (Thermo Scientiﬁc) at 50 °C for 1 h.
cDNA was used as PCR template in a 1:10 dilution and each sample
was run in triplicate. Quantitative PCR was done using Express SYBR
Green ER qPCR Supermix Universal (Life technologies), additional 1×
SybrGreen I (Life technologies) and 0.2 μM primer (Supplementary
Table 2) each on the DNA engine Opticon2 (Biorad) with the following
cycle conditions: primary denaturation at 95 °C for 3min, 35 cycleswith
30 s at 95 °C, 30s at 60 °C (36B4, Sox2)/55 °C (Oct4, Nanog, Klf4, c-Myc)
and 30 s at 72 °C followed by ﬂuorescence measurement. Absolute
quantiﬁcation was done for every single gene by dilution series of plas-
mid positive controls and set in relation to the reference gene 36B4.
2.15. Gene expression proﬁling
Six different samples includingHFFs, HFF-mRNA-iPSCs, IMR90ﬁbro-
blasts, IMR90-mRNA-iPSCs, foreskin-derived-viral-iPSCs (HFF-viral-
iPS) and hESCs control (H9 cell line) were used. At least 30 iPS colonies
were used per iPS sample. Total RNA was extracted with TriFast and
puriﬁed using GeneJet RNA puriﬁcation kit (Thermo scientiﬁc) accord-
ing to protocol. RNA integrity was conﬁrmed using Agilent 2100
bioanalyzer (Agilent technologies). Total RNAwas depleted of ribosom-
al RNA using the “RiboMinus Kit” (Life technologies) followed by ﬁrst
and second cDNA synthesis aswell as intermediate in vitro transcription
using the “WT cDNA Synthesis and Ampliﬁcation Kit” according to the
manufacturer's instructions (Affymetrix). cDNAwas fragmented and la-
beled with the “WT Terminal Labeling Kit” (Affymetrix) and hybridized
to Human Genome 1.0 ST Arrays. Washing and staining steps were per-
formedwith the Affymetrix Fluidics Station FS400. Arrayswere scanned
with a third-generation Affymetrix “GeneChipScanner 3000” equipped
with the “7G” upgrade.
2.16. SOM portraying of overall expression landscapes
A Self-OrganizingMap (SOM)was trained and analyzed as described
previously (Wirth et al., 2011;Wirth et al., 2012). The total gene expres-
sionmatrix of (N=6 samples) × (M=32,321 genes)was transformed
into a reduced matrix where the genes were clustered into K = 900
microclusters called metagenes after appropriate normalization and
centralization of the input expression data (Wirth et al., 2011). SOM-
machine learning provided strong visualization capabilities: the expres-
sion values of the metagenes in each of the samples were transferred
into a two-dimensional 30 × 30 mosaic picture ‘portraying’ the expres-
sion landscape of each sample using an appropriate color gradient: red
reﬂects strong over-expression compared to the mean expression of a
metagene; yellow and green tones indicate intermediate levels with
low or no differential expression; and blue corresponds to under-
expression. Each metagene collected similar ‘proﬁles’ of single genes
in the samples measured. Moreover, similar metagene proﬁles were
usually arranged in neighboring pixels in the maps thus forming
extended over- and under-expression spots. Importantly, each gene
was associated with one and the same metagene and thus with the
same position in all individual sample images.
2.17. Statistical analysis
All experimentswere repeated three times. One-way analysis of var-
iance (ANOVA) followed by Tukey test was used to determine whether
observed differences were statistically signiﬁcant between different
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cant using Sigma plot. Data were presented as mean ± SEM.
3. Results
3.1. Producing mRNA
For most factors (Oct4, Nanog, Klf4, Sox2) using linearized plasmid
or PCR products as IVT template lead to a high yield of full-sized IVT-
RNA (Fig. 1B). The IVT template consisted of the open reading frame
(ORF) of the gene of interest with a 5′Kozak translation initiation signal
and a T7 promoter sequence (Fig. 1A). The PCR products consisted of an
extended T7 promoter sequence (−27 to+1) to increase the promoter
strength (Tang et al., 2005). For c-Myc and TERT a PCR-derived template
was superior to linearized plasmid which otherwise gave no (TERT) or
minimal (c-Myc) yield. c-Myc's ORF is a difﬁcult IVT template due to
N80% G/C content. However reduction of the template size to the essen-
tial elements allowed for efﬁcient transcription. All factors had ORFs
below 1.5 kb except for the ORF of TERT which was over 3 kb.
While the IVT produced full length TERT-RNA, therewere also small-
er RNA fragments produced. This could be attributed to either a se-
quence inside the ORF resembling a T7 RNA polymerase termination
signal or to secondary structures that may be problematic for the T7-
RNA-polymerase to resolve. Hence, we tested a lower reaction temper-
ature for the IVT to enable the T7-RNA-polymerase to override a poten-
tial termination signal and a higher reaction temperature to denature
possible secondary structures. While the lower temperature yieldedFig. 1. Quality control of IVT-RNA. A) A representation of the reprogramming constructs (con
analyzed using Agilent Bioanalyzer. B) Comparison of IVT-RNA using either linearized plasm
RNA (at−80 °C), IVT-RNA with and without PolyA-tail and examples for high and low qualitythe same IVT RNA products mixture of small and full-length IVT-RNA,
the higher temperature leads to the full-length IVT RNA product with-
out smaller fragments. This suggests that secondary structures were
interfering with IVT (Supplementary Fig. 2). IVT-mRNA showed high
quality before and after PolyA-tailing (Fig. 1C) and were stable for
18 months at−80 °C (Fig. 1C).
3.2. Transfection efﬁciency
The efﬁciency of various mRNA transfection systems (electropora-
tion, FUGEN HD, Lipofectamine 2000 and jetPEI) were compared using
of GFP mRNA transfection. jetPEI and Lipofectamine 2000 showed a
signiﬁcantly better transfection rate (Supplementary Fig. 3).
3.3. Cytotoxicity of transfection reagents
JetPEI and lipofectamine 2000 were compared for effect on cell via-
bility in combination with each mRNA factor introduced. Comparison
revealed no signiﬁcant differences in the viability of the transfected
cells up to 72 h post-transfection (Fig. 2A). Cells transfected with jetPEI
reagent showed a trend to be more viable than Lipofectamine 2000.
Consequently, jetPEI was used in all following experiments.
3.4. Immune response
To identify a cellular immune response following mRNA transfec-
tion, levels of hIFN-γ and -α emitted by the transfected cells weretaining Oct4, Sox2, Klf4, c-Myc, Nanog, TERT or GFP) in pcDNA3. IVT-RNA samples were
id or PCR products as IVT template. C) Quality control of fresh IVT-RNA and stored IVT-
IVT-RNA.
Fig. 2. Stress of reprogramming factors-encodingmRNA. A) Comparison of viability after transfection. Datawere presented as percentage of cell viability compared to non-transfected cells
which set as a value=100. Cells used for analysiswere foreskinﬁbroblasts derived from3different donors at passage 3. B)& C) The level of hIFN-γ and -α in the supernatant of transfected
cells following mRNA transfection. Cells used for analysis were foreskin ﬁbroblasts derived from 3 different donors at passage 3. Graphs represent means ± SEM; n = 3. Lipo. =
Lipofectamine 2000. No trans. = Non-transfected cells. ONT = Oct4, Nanog, hTERT. OSK = Oct4, Sox2, Klf4. OSKMNT = Oct4, Sox2, Klf4, c-Myc, Nanog, hTERT.
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differences in levels were observed in the supernatant of transfected
cells using various factor combinations or single factors (Fig. 2B & C).
3.5. mRNA-transfection
To generatemRNA-iPSCs, ﬁbroblasts were transfectedwith different
mRNA-factor combinations. Results have been summarized in Supple-
mentary Fig. 5 and Supplementary Table 3. Formation of cellular aggre-
gates frommesenchymal to epithelial (MET) transitionwas observed in
ﬁve donor cells (foreskin 1, foreskin 1–1, foreskin 2, foreskin 3, and
IMR90 ﬁbro.) and they formed cellular aggregates after 2–4 transfec-
tions (Supplementary Fig. 5 and Supplementary Table 3). For some of
the donors (foreskin 2 & 3) only small cell aggregates were formed
which grew very slowly and could not be passaged more than once on
iMEFs. The colonies from foreskin ﬁbroblasts (foreskin 1) and IMR90 ﬁ-
broblasts showed the highest stability and could be passaged on iMEFs
(5 passages for foreskin 1 & over 37 passages for IMR90), thus they
were used for generation of stable cell lines and different pluripotency
characterization tests.
3.6. Protein expression of reprogramming factors
Persistence of reprogramming proteins in transfected cells was
monitored using ﬂow cytometry. High expression levels were found
for all factors following mRNA transfection (Fig. 3A). It was observed
that between 50% (GFP) to over 90% (c-Myc) of the cells expressed
the reprogramming proteins (Fig. 3A). Maximal protein expression ofreprogramming factors occurred between 24 h to 48 h after transfection
(Fig. 3B). In all instances the percentage of positive cells remained stable
between 24 h and 48 h but decreased 72 h after transfection (Fig. 3B).
More than 90% of the ﬁbroblasts were positive for Oct4, Sox2, Klf4, c-
Myc and Nanog protein 24 h and 48 h after transfection (Fig. 3B). GFP
and TERT were expressed signiﬁcantly less efﬁciently compared to the
other factors. The percentage of GFP positive cells was signiﬁcantly
(§P b 0.01) lower compared to the other factors 72 h after transfection
(Fig. 3B). The expression of hTERT-mRNA was signiﬁcantly (*P b 0.01,
+P b 0.01) lower compared to the other factors at 24 h, 48 h and 72 h
after transfection (Fig. 3B). The above results were conﬁrmed using
mean ﬂuorescent intensity (MFI) of positive cells. It was found that
the protein level for all factorswasmaximal 24h and 48 h after transfec-
tion and decreased signiﬁcantly (**P b 0.01) 72 h after transfection for
Sox2, Klf4, c-Myc and Nanog (Fig. 4B).
To conﬁrm that reprogramming proteins correctly localized as
endogenous protein, the mRNA-transfected cells were stained using
immunocytochemistry. The results demonstrated that each of the
factors was robustly expressed and correctly localized to the nucleus
(Fig. 4A). No reprogramming proteins were detected in non-
transfected ﬁbroblasts (Supplementary Fig. 4).
3.7. Reprogramming
For the establishment of stable mRNA-iPSCs, ﬁbroblasts (foreskin
& IMR90) were transfected with different factor combinations
using jetPEI, every 48 h over a period of 2 weeks. Cells underwent
mesenchymal-epithelial transition based upon morphological changes
Fig. 3. Protein expression of reprogramming factors. A) The graphs show expression efﬁciency of reprogramming proteins after a singlemRNA transfection. Non-transfected cells and cells
stainedwith secondary antibody were used as controls. B) Persistence of reprogramming proteins in the transfected cells monitored over 72 h using the gating strategy from A. Cells used
for analysis were foreskin ﬁbroblasts from 3 different donors at passage 3. Graphs represent means± SEM. n= 3. *P b 0.01= The percentage of hTERT positive cells 24 h, 48 h, and 72 h
after transfection compare to the other factors (Oct4, Sox2, Klf4, c-Myc and Nanog) at 24 h and 48 h after transfection. +P b 0.01 = The percentage of hTERT positive cells 72 h after
transfection compare to the other factors (Sox2, Klf4, c-Myc and Nanog) at 72 h after transfection. §P b 0.01 = The percentage of GFP positive cells 72 h after transfection compare to
the other factors (Oct4, Sox2, Klf4, c-Myc and Nanog) at 24 h and 48 h after transfection.
Fig. 4.Nuclear localization andmean ﬂuorescence intensity of reprogramming proteins. A) Proteins of reprogramming factors derived from the transfectedmRNAs localized in the nucleus
of transfected cells 24 h after transfection. Cells used for immunostainingwere foreskinﬁbroblasts at passage 3. Scale bars represent 100 μm. B) Themean ﬂuorescence intensity of human
foreskin ﬁbroblasts derived from 3 different donors represents the protein level for the analyzed reprogramming factors at different time points after single mRNA-transfection. Graphs
represent means ± SEM; n = 3; (**P b 0.01).
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Fig. 5. Reprogramming of human ﬁbroblasts usingmRNA.Morphological changes observed following transfectionswith jetPEI-mRNA. Transfectionwas controlled using GFP-mRNA (left-
lower picture). Arrows indicate the timing for repeated transfections with jetPEI. Images show human foreskin ﬁbroblasts on day 0, followed by the formation of small clusters with a
compact morphology (epitheliod morphology) on day 4 (upper pictures). The ﬁrst iPS colony-like structure was observed on day 6 and well-deﬁned border colonies appeared at day
8. Mature colonies with prominent nucleoli were visible on day 12 (upper pictures). The right-lower pictures represent HFF- and IMR90-mRNA-iPS colonies expanded on iMEF.
HFF = human foreskin ﬁbroblasts. HFF-mRNA-iPSCs = mRNA iPS cells derived from human foreskin ﬁbroblasts. IMR90-mRNA-iPSCs = mRNA iPS cells derived from human IMR90
ﬁbroblasts. Scale bars represent 100 μm.
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Switch of ﬁbroblast morphology to a compact, epithelioid morphology
was observed 4 days after the ﬁrst transfection, followed by the emer-
gence of typical hESC-like colonies with tight morphology by day 6.
Well deﬁned borders colonies were appeared at day 8 andmature colo-
nies with prominent nucleoli were visible at day 12 (Fig. 5). Two iPS cell
lines could be established (HFF-mRNA-iPSCs & IMR90-mRNA-iPSCs).
3.8. Teratoma assay
Trilineage differentiation potential was conﬁrmed in vivo by the for-
mation of teratomas derived from IMR90-mRNA-iPS colonies. Six mice
injected with iPSCs developed tumors within 7 weeks after injection
of the cells. Two of them were fully developed teratomas and showed
clearly all three germ layers. Control ﬁbroblasts injected were not caus-
ing any tumor growth. The results of hematoxylin–eosin staining
showed cell types of the three germ layers in the teratoma sections
(Fig. 6A).
3.9. Immunostaining
The expression of pluripotency markers in mRNA-iPSCs was assed
using immunostaining. The results showed the expression of
pluripotency markers in HFF-mRNA-iPS colonies compared to their
donor ﬁbroblasts (foreskin). Furthermore, nuclear localization of Oct4
and Nanog was conﬁrmed (Fig. 6B & Sup. Fig. 4B).
3.10. Karyotyping
To determine possible chromosomal aberrations following mRNA
reprogramming, GTG-banding was performed. The results of karyotype
analyses revealed similar chromosomal aberrations in IMR90-mRNA-iPSCs as compared to parental IMR90 ﬁbroblasts and no increase in ab-
errations was observed upon reprogramming (Fig. 6C and Supplemen-
tary Table 4).
Parental IMR90 ﬁbroblasts displayed numerical chromosomal aberra-
tions such as hyperdiploidy, hypotriploidy, triploidy, hypertriploidy,
hypotetrapoidy, hypertetraploidy and hypohexaploidy. IMR90-mRNA-
iPSCs; however, showed a trend to reduce numerical chromosomal aber-
rations (Supplementary Table 4). Some of the numerical chromosomal
aberrations such as hypertriploidy, hypertetraploidy andhypohexaploidy
were no longer observed in IMR90-mRNA-iPSCs. Furthermore, IMR90-
mRNA-iPSCs demonstrated a trend to decrease total and recurrent struc-
tural chromosomal aberrations compared to IMR90 parental ﬁbroblasts
(Supplementary Table 4).3.11. Pluripotency genes
IMR90-mRNA-iPS and HFF-mRNA-iPS colonies were passaged at
least 3 times before the expression of pluripotency genes were ana-
lyzed by qRT-PCR. Using a non-integrating reprogramming approach
with mRNA offers the advantage that mRNA will degrade after the
reprogramming procedure and does not interfere with analyzing
mRNA-expression levels.
In HFF-mRNA-iPS colonies Nanog, Oct4 and Klf4 were abundantly
expressed compared to the HFF donor showing no Nanog and very
low expression of Oct4 and Klf4 (Supplementary Fig. 6). In contrast
IMR90 ﬁbroblasts already had a high basic expression of Oct4, Sox2
and Klf4. In IMR90-mRNA-iPS colonies the expression of Sox2 and
Oct4 increased during reprogramming. Klf4 expression went down at
early passages but increased at later passages again. As in HFFs, Nanog
expression was induced in the IMR90-mRNA-iPSCs and increased with
higher passages (Fig. 7A).
Fig. 6. Characterization of mRNA-iPSCs. A) Teratoma formation assay. The pictures show hematoxylin–eosin staining of teratoma sections derived from IMR90-mRNA-iPS colonies
(passage 8) following subcutaneously injection. Cell types of the three germ layers have been shown in the teratoma sections. B) Immunostaining for pluripotency markers. Pictures
show the expression of pluripotency markers in HFF-mRNA-iPS colonies at passage 5. Scale bars represent 100 μm. C) Karyotype analyses of mRNA-iPSCs. Chromosomal GTG-banding
analysis of IMR90-mRNA-iPSCs (passage 37) and IMR90 parental ﬁbroblasts (passage 14) are shown. The pictures show presence of hyperdipoloidy and hypotetraploidy in both
IMR90 ﬁbroblasts and IMR90-mRNA-iPSCs.
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We generated SOMportraits of the expression data to get detailed
insights into comprehensive and individual structures of the expres-
sion landscapes. Therefore we trained a SOM using microarray ex-
pression data of our samples. The method ‘portrays’ the individual
expression landscape of each sample in terms of mosaic images.
The portraits generated are similar within the groups reﬂecting ho-
mogeneity of their overall expression landscapes (Fig. 7B). Visual in-
spection of the patterns in the portraits reveals two dominant
characteristics, namely spots of over-expressed metagenes (i.e. red
colored pixels) in the bottom-left and top-right regions of the map.
The former collects genes up-regulated in the HFF sample, the latter
collects genes up-regulated in stem cell controls (right edge) and
IMR90 samples (top and right edge). In particular, the portrait of
IMR90 ﬁbroblast differs from the HFF ﬁbroblast showing a global ex-
pression pattern closer to the stem cell controls. The pattern of
IMR90-mRNA-iPS resembles the hESC sample and particularly the
HFF-viral-iPS control (see the red spot in the top right corner of the
map, collecting up-regulated genes in the respective samples). The
molecular phenotypes of IMR90-mRNA-iPS, the viral iPS and the
hESC sample are thus very similar as seen by the overall expression
landscape portraits.4. Discussion
In this section, we brieﬂy take up some points requiring further
discussion regarding the results of the iPSCs analysis and then consider
the steps that are of particular technical interests with this method of
non-synthetic mRNA reprogramming.
4.1. Teratoma assay and pluripotency markers
mRNA-iPSCs showed hESC-typical pluripotencymarkers, morpholo-
gy, and differentiation into all three germ layers. The formation of tera-
tomas shows the feasibility of non-modiﬁed mRNA for generation of
fully reprogrammed iPSCs. This ﬁnding is in contrast with some studies
showing only the activation of pluripotency-associated genes upon de-
livery of non-modiﬁedmRNAs. Using non-modiﬁed RNA, Plew et al. did
not attain complete reprogramming to fully characterized iPSCs, since
they just obtained small cell aggregates which failed to expand on to
MEFs (Plews et al., 2010). Yakubov et al. obtained alkaline phosphatase
positive colonies after non-modiﬁed mRNA transfection, however; no
differentiation analysis and no teratoma formation were done, and
thus it is difﬁcult to evaluate the pluripotency of their iPSCs (Yakubov
et al., 2010). Other studies have shown teratoma formation of iPSC col-
onies generated by only modiﬁed RNA and not non-modiﬁed RNA
Fig. 7-.Molecular characterization of mRNA-iPSCs. A) Expression of pluripotency-related genes in IMR90-mRNA-iPS colonies (passage 3 & passage 36) and IMR90 parental ﬁbroblasts
(passage 6) analyzed by qRT-PCR. 36B4 was used as housekeeping gene. P.3 = passage 3. P.36 = passage 36. B) SOM portraying of the microarray expression resulted from 6 different
samples. The samples used contain 1) HFF (passage 7), 2) HFF-mRNA-iPSCs (passage 3), 3) IMR90 ﬁbroblasts (passage 6), 4) IMR90-mRNA-iPSCs (passage 11), 5) foreskin-derived-
viral-iPSCs (HFF-viral-iPS) (passage 20), 6) and hESCs control (H9 cell line).
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of teratoma formation from the mRNA-iPSCs generated by non-
modiﬁed RNA.
4.2. Karyotype
There is currently conﬂicting data regarding chromosomal abnor-
malities of iPSCs. Some publications suggest that chromosomal aberra-
tions occur upon reprogramming followed by further expansion of the
reprogrammed cells (Hussein et al., 2011; Gore et al., 2011; Lister
et al., 2011; Mayshar et al., 2010). Heng et al. demonstrated that chro-
mosomal changes can occur during adaptation of the iPSCs to prolonged
culture conditions (Heng et al., 2013). They reported chromosomal ab-
normalities in 4 out of 7 stable iPS cell lines following prolong passaging
(Heng et al., 2013). In another study karyotype analysis on more than
1700 human iPS cell lines were performed and the occurrence of chro-
mosomal aberrations was 12.5% (Taapken et al., 2011). Two reports no-
ticed that reprogramming could restore chromosomal aberrations in
iPSCs generated from disease-associated chromosomal abnormality
(known as a ring chromosome) (Bershteyn et al., 2014; Kim et al.,
2014). In this study, IMR90-mRNA-iPSCs maintained some of the pre-
existing chromosomal aberrations of the parental IMR90 ﬁbroblasts
and no structural and numerical aberrations were acquired upon
reprogramming. mRNA-iPSCs displayed a tendency for more stabilityand reduction of chromosomal aberrations. Numerical chromosomal
aberrations such as hypertriploidy, hypertetraploidy and
hypohexaploidy were not observed in mRNA-iPSCs which might indi-
cate a selective advantage favoring normal karyotypes upon iPS gener-
ation or conﬁrm that reprogramming itself revert chromosomal
aberrations to a more stable karyotype.4.3. Pluripotency associated gene expression
HFF- as well as IMR90-mRNA-iPSCs could be characterized by their
pluripotency gene expression. The induced expression of Nanog in
particular is essential for the pluripotency transcriptional circuitry and
mediating self-renewal maintenance of stem cells (Silva et al., 2009;
Theunissen et al., 2011).
IMR90 cells are of fetal originwhichmay explain the pre-existing ex-
pression of several pluripotency genes. The expression of Klf4 in fetal
lungs is induced by oxygen (Shields et al., 1996; Jean et al., 2013).
Hence, the intermittent down-regulation of Klf4 at passage 3 of the
IMR90-mRNA-iPSCs may be due to cultivation in hypoxia with a subse-
quent up regulation attributable to the general pluripotency proﬁle of
the proliferating IMR90-mRNA-iPSCs.
The SOM analysis of the gene expression showed that the portrait of
IMR90-mRNA-iPSCs features amolecular phenotype closely resembling
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to the original HFF.
HFF and IMR90 ﬁbroblast already differ in their basic gene expres-
sion. The fetal IMR90 ﬁbroblast reveals a portrait that resembles more
the portrait of the hESC than the adult HFF.
In general, fetal and adult ﬁbroblasts have different properties.
Navarro et al. showed different gene expression pattern between fetal
and adult lung ﬁbroblast especially regarding components of the TGF-
β family signaling pathways (Navarro et al., 2009). Since these path-
ways are involved during embryonic development and later on regulate
proliferation, tissue repair and differentiation, it seems likely that they
are also involved in the success of reprogramming.
4.4. Technical advances
ThemRNA-based reprogramming has not yet been used routinely in
many laboratories. In this paper we describe some crucial steps for the
efﬁcient generation of mRNA-derived iPSCs, focusing on some crucial
technical details for the successful application of this method.
4.5. Non-synthetic mRNA
Our protocol allows for the efﬁcient IVT production of 5′-capped and
3′-polyadenylatedmRNAwith easymodiﬁcations even for difﬁcult tem-
plates with a high G/C content or a long sequence. The use of PCR prod-
ucts as IVT template removes the need to clone IVT expression cassettes
if the ORF of the gene is already available. The alternative system for
mRNA production eliminates the need to remove residual 5′-triphos-
phates from non-capped IVT-RNA which is necessary step for cap ana-
logs. The cap analog system produces only ~80% capped RNA. Instead,
our approach is to use a V. virus-derived capping enzymewhich ensures
100% capped IVT-RNA transcripts. The additional use of the V. virus-
derived 2′-O-Methyltransferase creates a cap1 structure found in higher
eukaryotes and providing a higher translation efﬁciency (Kuge et al.,
1998).
4.6. Reduced immunogenicity and cytotoxicity followingmRNA transfection
It has been discussed that transfection-associated activation of in-
nate intracellular immunity pathways triggered by foreign nucleic acid
like IVT-RNA leads apoptosis (Warren et al., 2012; Angel & Yanik,
2010; Drews et al., 2012). This is one of the main barriers for successful
induction of pluripotency throughmRNA-reprogramming (Drews et al.,
2012). Exogenous RNAs and particularly the uncapped 5′-triphosphate
(3pRNA) end-RNAs are pathogen-associated molecular pattern for
toll-like receptors and RNA sensors (RIG-I and PKR) (Angel & Yanik,
2010; Karikó et al., 2005). Consequently, a key step in cellular mRNA
processing is the addition of a 5′ cap structure. Different capping sys-
tems could be inserted to the 5′-end of RNA. To suppress the immune
response followingmRNA transfection,Warren et al. utilized cap analog
ARCA with modiﬁed nucleosides. Even so upregulation of a number of
interferon response genes was observed (Warren et al., 2010). Conse-
quently, they applied recombinant B-18-R-protein, as a suppressor of
type I interferon to inhibit innate immune response. Application of
interferon suppressors such as B-18-R-protein might have an effect on
reprogramming. Mah et al. claimed that B-18-R supplementation
yielded Nanog-positive iPSCs (Mah et al., 2011). Some groups have
recently clariﬁed the role of B-18-R-protein on reprogramming
(Yoshioka et al., 2013). The use of B-18-R-protein for mRNA-
reprogramming raises the question afterward whether the generated
iPSCs are derived from reprogramming-mRNAs or positive effect of B-
18-R-protein.
However, Warren et al. veriﬁed intracellular immune reactions only
as per gene expression and not on the protein level. In contrast, we have
searched for manifestation of an interferon immune response following
mRNA transfection on the protein level, ﬁnding no increased levels ofIFN-γ and -α as hallmarks of immune response in the supernatant of
transfected cells. In our hands, applying B-18-R-protein, as a suppressor
of type I interferon is not needed. We used V. virus-derived capping en-
zyme to insert non-modiﬁed natural cap 1 to 5′ endof RNA. Such system
ensures 100% proper cap orientation for the resultant transcripts com-
pared to cap analog ARCAwhere only ~80% of IVT-RNAs will be capped.
The proper capping of in vitro transcribed RNA (100% capping of
transcripts) could contribute to mitigate immune response, and conse-
quently reduce cytotoxicity. This could support repeated mRNA trans-
fections for the iPS generation. However, the use of jetPEI (the effect
of transfection reagent) itself might reduce cytotoxicity following
mRNA transfection. We could conﬁrm that jetPEI transfection could be
used for mRNA-iPSCs generation with minimal cytotoxicity. We hy-
pothesized that jetPEI itself might minimize cellular defensive actions
following foreign nucleic acid transfection, and therefore minimize
toxicity. As reported by a number of studies, application of some
transfection reagents minimize cellular defensive actions following for-
eign nucleic acid transfection, and therefore minimize toxicity (Jensen
et al., 2014).
4.7. Long-lasting reprogramming protein production
The short half-life of RNA molecules necessitates repeated transfec-
tions to generate mRNA-iPSCs. Thus, highly stable mRNA is desired to
reduce transfection frequency. Especially the poly(A)tail length inﬂu-
ences the stability of mRNA molecules and affects the translation. The
subsequent addition of a poly(A)tail using a PolyA polymerase allows
for tail lengths resembling the endogenous lengths of poly(A)tails of
mRNAs in mammalian cells being approximately 200–300 adenosine
residues long (Sheets &Wickens, 1989). Thismay allow for a higher sta-
bility of IVT-mRNAs compared to other reports (Warren et al., 2010)
using shorter poly(A)tails of 120 residues. These reports also showed
a reduction in expression of mRNA-introduced protein already 36 h
after transfection, necessitating a daily transfection cycle (Warren
et al., 2010; Mandal & Rossi, 2013). The long-lasting protein levels in
our study enabled us to perform repeated transfection just every 48 h.
The use of a cap1-structure naturally occurring in higher eukaryotic
cells allows for a higher translation efﬁciency compared to cap analogs
like ARCA resembling a cap0-structure.
Still, even while the transfection efﬁciency as well as the size of the
mRNA molecules of the factors (OSKMN) was comparable, the protein
levels of Klf4 and c-Myc were found to be higher compared to the
other factors. The differences in the amount may be due to the different
half-life times of the proteins.
The reported turnover times are highly variable, ranging from 24 h
(Holt et al., 1996) to only 2.1 h for hTERT (Jung et al., 2013). While the
half-life of c-Myc protein is considered to be short with about 20–
30 min (Salghetti et al., 1999), it is known that especially under condi-
tions like stress the half-life of c-Myc protein can increase (Alarcon-
Vargas et al., 2002). The same is true for Nanog since several studies
reported a half-life to be about 2 h (Ramakrishna et al., 2011; Chae
et al., 2012; Abranches et al., 2013) while Filipczyk et al. measured a
half-life of about 5.5 h (Filipczyk et al., 2013).
The percentages of GFP and hTERT positive cells were found to be
lower compared to the other factors. This could be due to less efﬁcient
transfection of mRNA, (e.g. hTERT mRNA is larger than the other factor
mRNAs) or due to a lower efﬁciency of protein translation.
4.8. Colony formation
The ﬁrst sign of reprogramming was that the ﬁbroblast morphology
changed to a compact epithelioid morphology, indicative of MET (initi-
ation phase of reprogramming). This is consistent with reports by other
groups (Samavarchi-Tehrani et al., 2010; Li et al., 2010).
We could observe the ﬁrst colony-like structures at day 8 compared
to day 19 in the report by Rossi et al. (Warren et al., 2010). This might
672 L. Rohani et al. / Stem Cell Research 16 (2016) 662–672have been due to the use of low oxygen, which has been reported to
promote reprogramming (Utikal et al., 2009; Yoshida et al., 2009).
Nevertheless the efﬁciency of mRNA-reprogramming and the stabil-
ity of generated colonies vary depending upon the origin, proliferative
potential and genetic background of the ﬁbroblasts. Taken together,
the methodology we describe cuts mRNA reprogramming time.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.03.008.
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